Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

AKCEA THERAPEUTICS

Home Clinical Trial Sponsors and OrganizationsAKCEA THERAPEUTICS

AKCEA THERAPEUTICS

1906 Ashton Dr, Greensboro, North Carolina, United States

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

19

5 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 2

7

36.8%

Phase 1

6

31.6%

Phase 3

2

10.5%

Phase 4

1

5.3%

Trial Status Distribution

Active, not recruiting

4

21.1%

Completed

10

52.6%

No Longer Available

1

5.3%

Not yet recruiting

1

5.3%

Terminated

2

10.5%

Withdrawn

1

5.3%

Clinical Trials

Trials sponsored by this organization (19)

TEGSEDI Pregnancy Surveillance Program

Not yet recruiting

Dec 202520 participants

A Non-interventional Cohort Safety Study of Patients With hATTR-PN

Active, not recruiting

Sep 2021202 participants

A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN

Jan 20218 participants

Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)

Jun 20184 participants

Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

Mar 201816 participants

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

Jan 2018114 participants

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel

Dec 201718 participants

Page 1 of 3

Approvals

No approval data available

News

Catalyst Pharmaceuticals Appoints Dr. William Andrews as Chief Medical Officer to Lead Rare Disease Strategy

- Catalyst Pharmaceuticals appointed Dr. William T. Andrews as Chief Medical Officer, succeeding retiring Dr. Gary Ingenito after his successful 10-year tenure with the company. - Dr. Andrews brings 24 years of global biopharmaceutical experience with 18 years specifically focused on rare diseases, having previously served as CMO at multiple biotech companies. - The leadership change coincides with strong financial performance, including a 13% stock price increase over the last quarter and 443.67% total return over five years. - The appointment aims to strengthen Catalyst's strategic direction in rare diseases and support continued growth of key products AGAMREE and FIRDAPSE.

On this page

Overview
Clinical Trials19
Approvals
News1

Back to Organizations